Bronchopulmonary dysplasia

Pediatrics in Review

Volumn 33, Issue 6, 2012, Pages 255-263

  Kair, Laura R ^a   Leonard, Douglas T ^a,b   Anderson, JoDee M ^c,d,e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Neonatal Specialists   (United States)

^c Pediatric Simulation Education   (United States)

^d STABLE Simulation Program   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CAFFEINE; CORTICOSTEROID; DIURETIC AGENT; RETINOL; SURFACTANT;

ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BAROTRAUMA; CARDIOVASCULAR DISEASE; CHORIOAMNIONITIS; CHRONIC DISEASE; CHRONIC DRUG ADMINISTRATION; CHRONIC LUNG DISEASE; CORTICOSTEROID THERAPY; DEVELOPMENTAL DISORDER; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; EXTREMELY LOW BIRTH WEIGHT; EXTUBATION; FOLLOW UP; HISTORY OF MEDICINE; HUMAN; INTUBATION; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG FIBROSIS; MUSCLE HYPERTROPHY; NEWBORN APNEA; NEWBORN CARE; NEWBORN SEPSIS; OXYGEN THERAPY; PATENT DUCTUS ARTERIOSUS; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; RESPIRATORY TRACT INFLAMMATION; UREAPLASMA; VENTILATOR;

ANTI-INFLAMMATORY AGENTS; BRONCHOPULMONARY DYSPLASIA; DIET THERAPY; DIURETICS; HUMANS; INFANT, NEWBORN; PROGNOSIS; RESPIRATORY SYSTEM AGENTS; UNITED STATES;

EID: 84862318167     PISSN: 01919601     EISSN: 15263347     Source Type: Journal    
DOI: 10.1542/pir.33-6-255     Document Type: Article

References (37)

1. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357-368
2. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-1729 (Pubitemid 32578778)
3. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82(4):527-532
4. Wright CJ, Kirpalani H. Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies? Pediatrics. 2011;128(1):111-126
5. Ehrenkranz RA, Walsh MC, Vohr BR, et al; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116(6):1353-1360 (Pubitemid 46056482)
6. Stoll BJ, Hansen NI, Bell EF, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126(3):443-456
7. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res. 1999;46(6):641-643
8. Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics. 2009;123(6):1562-1573
9. Lahra MM, Beeby PJ, Jeffery HE. Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study. Pediatrics. 2009;123(5):1314-1319
10. Schelonka RL, Katz B, Waites KB, Benjamin DK Jr. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J. 2005;24(12):1033-1039 (Pubitemid 43011055)
11. Kugelman A, Durand M. A comprehensive approach to the prevention of bronchopulmonary dysplasia. Pediatr Pulmonol. 2001;doi 10.1002/ ppul.21508
12. Watterberg KL, Scott SM, Backstrom C, Gifford KL, Cook KL. Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics. 2000;105(2):320-324 (Pubitemid 30078671)
13. Vento M, Moro M, Escrig R, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. Pediatrics. 2009;124(3). Available at: www.pediatrics.org/cgi/content/full/124/ 3/e439
14. Atkinson SA. Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. J Nutr. 2001;131(3):942S-946S (Pubitemid 32199175)
15. An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J. 2010;40(3):131-136
16. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120(6):1260-1269 (Pubitemid 350223677)
17. Anderson PJ, Doyle LW. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol. 2006;30(4):227-232 (Pubitemid 44081949)
18. Short EJ, Kirchner HL, Asaad GR, et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med. 2007;161(11):1082-1087 (Pubitemid 350074841)
19. Fok TF. Adjunctive pharmacotherapy in neonates with respiratory failure. Semin Fetal Neonatal Med. 2009;14(1):49-55
20. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001;1:1
21. Ballard HO, Shook LA, Bernard P, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial. Pediatr Pulmonol. 2011;46(2):111-118
22. Tyson JE, Wright LL, Oh W, et al; National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999;340(25):1962-1968 (Pubitemid 29288272)
23. Ambalavanan N, Tyson JE, Kennedy KA, et al; National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005;115(3). Available at: www.pediatrics.org/cgi/content/ full/115/3/e249
24. Biniwale MA, Ehrenkranz RA. The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol. 2006;30(4):200-208 (Pubitemid 44062678)
25. Schmidt B, Roberts RS, Davis P, et al; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-2121 (Pubitemid 43736611)
26. Lauterbach R, Szymura-Oleksiak J, Pawlik D, Warchoł J, Lisowska-Miszczyk I, Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. J Matern Fetal Neonatal Med. 2006;19(7):433-438 (Pubitemid 44272918)
27. Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics. 2011;127(2):363-369
28. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007;4(4):CD003063
29. Thome UH, Carlo WA. Permissive hypercapnia. Semin Neonatol. 2002;7(5):409-419 (Pubitemid 35440226)
30. Hagadorn JI, Furey AM, Nghiem TH, et al; AVIOx Study Group. Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks' gestation: the AVIOx study. Pediatrics. 2006;118(4):1574-1582 (Pubitemid 46393804)
31. Wheeler K, Klingenberg C, McCallion N, Morley CJ, Davis PG. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev. 2010;11(11):CD003666
32. Kugelman A, Feferkorn I, Riskin A, Chistyakov I, Kaufman B, Bader D. Nasal intermittent mandatory ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a randomized, controlled, prospective study. J Pediatr. 2007;150(5):521-526, 526, e1
33. Oh W, Poindexter BB, Perritt R, et al; Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005;147(6):786-790 (Pubitemid 41774834)
34. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2007; (4):CD001969
35. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2002; (1):CD001453
36. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2002; (1):CD001817
37. Denjean A, Paris-Llado J, Zupan V, et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. Eur J Pediatr. 1998;157(11):926-931 (Pubitemid 28506555)